1.	Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 19 to 90 Sponsor: Other Protocol IDs: SuMo-Sec-01, PEI 0899/01, IRB 07/03, NCT00108875
2.	Vaccination With Peptides From Anti-apoptotic Proteins in Relapsed Multiple Myeloma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 90 Sponsor: Other Protocol IDs: 2006-003619-29, NCT01272466
3.	Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: P009-2010DR1082, NCT01308294
4.	Phase II Randomized Study of a Lymphodepleting Conditioning Regimen Comprising Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation Followed by Anti-MART-1 and Anti-gp100 T-Cell Receptor Gene-Engineered Autologous Peripheral Blood Lymphocytes, High-Dose Aldesleukin, and gp100:154-162 or MART-1:26-35(27L) Peptide Vaccination in Patients With Metastatic Melanoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-09-C-0051, 09-C-0051, NCI-P08428, NCT00814684
5.	Safety of Peptide Vaccination for Patients with Myelodysplastic Syndrome Phase: Phase I Type: Treatment Status: Active Age: 18 to 85 Sponsor: NHLBI Protocol IDs: 060062, 06-H-0062, NHLBI-06-H-0062, NCT00270452
6.	Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer Phase: Phase I Type: Treatment Status: Active Age: 20 to 80 Sponsor: Other Protocol IDs: AUGIS-001, NCT00624182
7.	Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer Phase: Phase I Type: Treatment Status: Active Age: 20 to 80 Sponsor: Other Protocol IDs: TPR07-079, NCT00632333
8.	Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Non-small Cell Lung Cancer Phase: Phase I Type: Treatment Status: Active Age: 20 to 85 Sponsor: Other Protocol IDs: SUMS-21-72, UMIN000003189, NCT01069575
9.	Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Small Cell Lung Cancer Phase: Phase I Type: Treatment Status: Active Age: 20 to 75 Sponsor: Other Protocol IDs: SUMS-21-74, UMIN000003191, NCT01069653
10.	Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: I 171010, NCI-2010-02042, NCT01250470
11.	Safety Study of Multiple-Vaccine to Treat Metastatic Breast Cancer Phase: Phase I Type: Treatment Status: Active Age: 20 to 85 Sponsor: Other Protocol IDs: MBCCTA-001-STT, NCT01259505
12.	A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 15781, NCT01585350
13.	NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: LUD2012-004, NCT01810016
14.	Randomized Study of the Effects of Sargramostim (GM-CSF) Versus Incomplete Freund's Adjuvant (Montanide ISA-51) Versus GM-CSF and Montanide ISA-51 on Dermal Dendritic Cells at or Around the Tumor Site in Patients With Stage I or II Melanoma Phase: No phase specified Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Treatment Status: Active Age: 18 to 85 Sponsor: NCI Protocol IDs: UVACC-MEL-38, UVACC-14499, UVACC-HIC-8380